Poliseno, M.; Lacedonia, D.; Niglio, M.; De Gregorio, F.; Minafra, G.A.; Campanino, T.; Giganti, G.; Scioscia, G.; Santantonio, T.A.; Foschino Barbaro, M.P.;
et al. Real-Life Advantages and Limits of Baricitinib for the Late Treatment of Adults Hospitalized with COVID-19. BioMed 2023, 3, 236-245.
https://doi.org/10.3390/biomed3020021
AMA Style
Poliseno M, Lacedonia D, Niglio M, De Gregorio F, Minafra GA, Campanino T, Giganti G, Scioscia G, Santantonio TA, Foschino Barbaro MP,
et al. Real-Life Advantages and Limits of Baricitinib for the Late Treatment of Adults Hospitalized with COVID-19. BioMed. 2023; 3(2):236-245.
https://doi.org/10.3390/biomed3020021
Chicago/Turabian Style
Poliseno, Mariacristina, Donato Lacedonia, Mariangela Niglio, Federica De Gregorio, Graziano Antonio Minafra, Terence Campanino, Giulio Giganti, Giulia Scioscia, Teresa Antonia Santantonio, Maria Pia Foschino Barbaro,
and et al. 2023. "Real-Life Advantages and Limits of Baricitinib for the Late Treatment of Adults Hospitalized with COVID-19" BioMed 3, no. 2: 236-245.
https://doi.org/10.3390/biomed3020021
APA Style
Poliseno, M., Lacedonia, D., Niglio, M., De Gregorio, F., Minafra, G. A., Campanino, T., Giganti, G., Scioscia, G., Santantonio, T. A., Foschino Barbaro, M. P., & Lo Caputo, S.
(2023). Real-Life Advantages and Limits of Baricitinib for the Late Treatment of Adults Hospitalized with COVID-19. BioMed, 3(2), 236-245.
https://doi.org/10.3390/biomed3020021
